All In Biotech

Drug Trial Radar · NCT02418455

Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old

Last checked: Nov 20, 2026Latest source record: Oct 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

8

Actual

Start

Jul 21, 2015

Primary completion

Mar 26, 2019

Study completion Mar 26, 2019

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Apr 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 day, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to evaluate the effect of UX003 treatment in pediatric MPS VII participants less than 5 years of age on safety, tolerability, and efficacy as determined by the reduction of urinary glycosaminoglycans (uGAG) excretion.

Conditions

  • Sly Syndrome
  • MPS VII
  • Mucopolysaccharidosis
  • Mucopolysaccharidosis VII

Interventions

  • UX003Drug

    solution for intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in uGAG Excretion (LC-MS/MS-DS) at Week 48Time frame: Baseline (Week 0), Week 48
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEsTime frame: From first dose of study drug until 30 days after the last dose of study drug. Mean (SD) treatment duration was 98.11 (29.02) weeks

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's National Health System

    Washington D.C., District of Columbia

  • New York University Langone Medical Center

    New York, New York

  • University of Utah Hospital

    Salt Lake City, Utah

  • Centro Hospitalar do Porto

    Porto, Portugal

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.